Skip to content

The Italian Multiple Sclerosis and Related Disorders Register

Registro Italiano Sclerosi Multipla e Patologie Correlate

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07636876
Acronym
RISM
Enrollment
96000
Registered
2026-06-09
Start date
2014-09-17
Completion date
2026-07-01
Last updated
2026-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinically Isolated Syndrome, Demyelinating Diseases of the Central Nervous System, Multiple Sclerosis, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Neuromyelitis Optica, Radiologically Isolated Syndrome

Keywords

Epidemiology, Pharmacoepidemiology, Disease Registry, Patient Registry, Disease Modifying Treatment, Autoimmune Diseases, Multiple Sclerosis, Real-World Data, Real-World Evidence

Brief summary

The Italian Multiple Sclerosis and Related Disorders Register (Registro Italiano Sclerosi Multipla e Patologie Correlate - RISM) is an observational cohort study that aims to create an organised multicentre structure to collect data of all patients with multiple sclerosis (MS) followed in the various MS clinical centers in Italy (a near population-level). RISM is promoted and funded by the Italian Multiple Sclerosis Foundation (Fondazione Italiana Sclerosi Multipla - FISM ETS). In 2014, FISM and the University of Bari constituted a "Research Unit", which manages the project and acts on behalf of the participating MS clinical centers. The governance of RISM includes an Executive Committee (chaired by FISM and the University of Bari) with administrative and organisational roles and a Scientific Committee, which oversees the scientific initiatives, promotes specific strategic projects, and approves requests for access to centralised data for further research projects. RISM aims to address high-priority research areas pertaining to: public healthcare area (quality of care, health optimisation such as economic optimisation, social and welfare information, access to healthcare treatments and healthcare services) and research area (epidemiology, rare MS disease forms such as primary progressive MS, pediatric MS as well as early and preclinical/subclinical disease stages represented by clinically isolated syndromes and radiologically isolated syndromes, treatment optimisation such as prognostic factors and predictive models of disease course, adherence to treatments, treatment efficacy, and safety). RISM also includes patients with Neuromyelitis Optica Spectrum Disorders (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD).

Detailed description

In 2000, the Italian collection of MS clinical data started at different Italian MS centres in the framework of the Italian Multiple Sclerosis Database Network (MSDN). At the end of 2014, the Italian Multiple Sclerosis and Related Disorders Register (RISM) was set up to create a national data source collecting demographic and clinical data on people with multiple sclerosis. Currently, data are collected through a web-based system - the RISM-App - developed ad hoc for the study. Each centre can enter the data after identification through a personalised password. In RISM, each patient is assigned to a specific centre and has a unique valid code identifier, obtained through the patient encrypted fiscal code. The RISM-App includes 1,475 variables and is organised into sections and subsections. According to the current clinical practice, the following information is requested in the RISM-App: identification/personal data, onset and diagnosis (anamnesis), follow-up visits (EDSS, safety, and relapses), adverse events (clinical events), treatments, non-pharmacological treatments, risk assessment, pregnancies, COVID-19, co-morbidity, familiar anamnesis, tests and scales, laboratory exams, magnetic resonance, liquor, evoked potentials, EEG, ECG, blood pressure, eye examination, optical computerised tomography. To harmonise data collection, the RISM-App integrates several standardised databases, including FarmaDati, MedDRA, ICD-9-CM, and EUROCAT (for congenital anomalies). Continuous data monitoring is ensured through regular communication with centres, biannual ad hoc reports providing both overall and centre-specific quality and descriptive indicators, data verification requests, and training on standardised data collection procedures. In addition, a set of built-in validation checks - such as consistency between date of birth, diagnosis, first visit, and treatment - is implemented in the RISM-App to prevent conflicting entries.

Interventions

None listed

Sponsors

Fondazione Italiana Sclerosi Multipla
Lead SponsorOTHER
University of Bari Aldo Moro
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of definite or probable multiple sclerosis * Clinical diagnosis of CIS or RIS * Clinical diagnosis of NMOSD or MOGAD * Patient is able to understand and sign the informed consent to participate in the study

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Number of cases included1 yearTotal number of subjects with multiple sclerosis and related disorders (NMOSD and MOGAD) included in the study.
Description of demographic characteristics1 yearFemale/male ratio.
Expanded Disability Status Scale (EDSS)1 yearNumber of EDSS scores collected every 6 and 12 months by each center.
Disease-modifying treatment description1 yearDistribution of patients with/without a DMT prescription.
Magnetic Resonance Imaging (MRI)1 yearNumber of MRI exams collected every year by each center.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 10, 2026